超微细化棕榈酰乙醇胺附加给药治疗新发灼口综合征。
Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome.
作者信息
Chirchiglia Domenico, Chirchiglia Pasquale, Marotta Rosa, Gallelli Luca
机构信息
Department of Neurosurgery, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy,
Department of Medical-Surgical Sciences, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy.
出版信息
Int Med Case Rep J. 2019 Feb 15;12:39-42. doi: 10.2147/IMCRJ.S194403. eCollection 2019.
AIM
The purpose of this study was to treat burning mouth syndrome (BMS) with a combination of painful gabapentin and ultramicronized palmitoylethanolamide (umPEA), in an attempt to improve the severe symptomatology of BMS.
METHODS
We examined the case of a 60-year-old male, suffering from late-onset burning mouth syndrome. He found that gabapentin had a poor control of symptoms, thus we added umPEA, after administering a Visual Analog Scale (VAS), showing a score of 8-9. The patient also underwent laboratory examinations, neuroimaging exams such as brain CT/MRI and others, which all showed normal results.
RESULTS
The result of combined therapy was satisfactory. After 3 months, the frequency and intensity of the pain had improved considerably, as demonstrated clinically and by VAS, with a score of 5.
CONCLUSION
BMS is an oral pain-burning syndrome scarcely responsive to therapy. The most widely used medications are GABA-like substances, antidepressants, topiramate. In this case, we used PEA, which proved effective in the treatment of BMS, as well as in neuropathies and migraines.
目的
本研究旨在采用加巴喷丁与超微化棕榈酰乙醇胺（umPEA）联合治疗灼口综合征（BMS），以改善BMS的严重症状。
方法
我们研究了一名60岁男性迟发性灼口综合征患者的病例。他发现加巴喷丁对症状控制不佳，因此在进行视觉模拟量表（VAS）评分显示为8 - 9分后，我们加用了umPEA。该患者还接受了实验室检查、脑CT/MRI等神经影像学检查，所有结果均正常。
结果
联合治疗结果令人满意。3个月后，疼痛的频率和强度在临床及VAS评分中均有显著改善，评分为5分。
结论
BMS是一种对治疗反应不佳的口腔灼痛综合征。最常用的药物是γ-氨基丁酸（GABA）类物质、抗抑郁药、托吡酯。在本病例中，我们使用的PEA被证明对BMS以及神经病变和偏头痛的治疗有效。
Zotero 插件